HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Low Dose Ads Urge Consumers To “Do More” In Cardiac Prevention

This article was originally published in The Tan Sheet

Executive Summary

Bayer seeks to increase consumer awareness of low-dose aspirin for primary prevention of heart attacks in a television spot that broke June 23

You may also be interested in...



Aspirin For MI Primary Prevention Indication Needs More Study, Panel Says

A long-term randomized prospective trial of at least 15,000 patients would be needed to adequately support professional aspirin labeling on primary prevention of myocardial infarction, according to members of FDA's Cardiovascular & Renal Drugs Advisory committee

Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition

Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel